Vildagliptin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
===Better Known as: Galvus=== | ===Better Known as: Galvus=== | ||
* Marketed by: Novartis | * Marketed by: Novartis | ||
* Major Indication: | * Major Indication: [[Hyperglycemia & Type II Diabetes]] | ||
* Drug Class: | * Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor | ||
* Date of | * Date of EMA Approval: 2008 | ||
* 2009 Sales: | * 2009 Sales: N/A | ||
* Importance: | * Importance: Part of a new generation of DPP-4 Inhibitors. Was not approved by the FDA due to concerns over kidney impairment associated with the drug. It was however approved by the European Medicines Agency for use within the EU. Increasing evidence exists that all DPP-4 inhibitors can to certain malignant cancers.<ref>PMID:15735018</ref> | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
